Our findings also suggest that SIRT1 and SIRT6 also play a coordinate role in fine-tuning FOXO3 acetylation and therefore lapatinib sensitivity by setting a threshold for the de-acetylation activity in both lapatinib sensitive and resistant cancer cells. Here, FOXO3 is linked to cancer.